Literature DB >> 18329608

Keeping adenovirus away from the liver.

Michael J Imperiale1.   

Abstract

While adenovirus holds many advantages as a vector for gene delivery, much of its full potential has been limited by the tendency of the most commonly used vectors to target the liver upon systemic delivery, resulting in unacceptable toxicity. Recently in Cell, Waddington et al. unmasked the virus-host interactions that lead to hepatic transduction. The results point a way toward avoiding this pathway during development of future generations of adenovirus vectors.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18329608     DOI: 10.1016/j.chom.2008.02.007

Source DB:  PubMed          Journal:  Cell Host Microbe        ISSN: 1931-3128            Impact factor:   21.023


  4 in total

1.  Mutation in fiber of adenovirus serotype 5 gene therapy vector decreases liver tropism.

Authors:  Zhen Wang; Baoming Wang; Junfang Lou; Jingyi Yan; Lei Gao; Ranshen Geng; Bin Yu
Journal:  Int J Clin Exp Med       Date:  2014-12-15

2.  Substitution of adenovirus serotype 3 hexon onto a serotype 5 oncolytic adenovirus reduces factor X binding, decreases liver tropism, and improves antitumor efficacy.

Authors:  Joshua J Short; Angel A Rivera; Hongju Wu; Mark R Walter; Masato Yamamoto; J Michael Mathis; David T Curiel
Journal:  Mol Cancer Ther       Date:  2010-08-24       Impact factor: 6.261

Review 3.  Gene Therapy Leaves a Vicious Cycle.

Authors:  Reena Goswami; Gayatri Subramanian; Liliya Silayeva; Isabelle Newkirk; Deborah Doctor; Karan Chawla; Saurabh Chattopadhyay; Dhyan Chandra; Nageswararao Chilukuri; Venkaiah Betapudi
Journal:  Front Oncol       Date:  2019-04-24       Impact factor: 6.244

4.  CXCL12 retargeting of an adenovirus vector to cancer cells using a bispecific adapter.

Authors:  Shilpa Bhatia; Samia M O'Bryan; Angel A Rivera; David T Curiel; J Michael Mathis
Journal:  Oncolytic Virother       Date:  2016-11-11
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.